spacer
home > ict > spring 2008 > more than a sleeping partner
PUBLICATIONS
International Clinical Trials

More Than a Sleeping Partner

Martin King of LCG Bioscience outlines some of the most common sleep disorders and their implications, and explains the techniques available for practitioners undertaking specialist sleep trials

Sleep medicine is a fairly new speciality, having been only properly developed within the last 20 years or so. There are currently 89 sleep disorders on the list of International Classification of Sleep Disorders and this is growing all the time (1). The disorders are divided into three groups: dyssomnias, which can be insomnia or hypersomnia (where people sleep too much); parasomnias, which describe undesired events that occur alongside sleep; and medical and psychiatric disorders that affect sleep.

The main area of interest for new sleep drug development by the pharmaceutical industry is the dyssomnia group. It is estimated that 30-35 per cent of the population suffer from some form of insomnia at any time and the economic consequences are dramatic. Insomniacs seem to have more frequent visits to their doctor for other complaints, they probably suffer low mood, and they lose more days from work. So, in terms of the cost to the nation, insomnia is important.

THE MARKET FOR SLEEP MEDICATION

The low number of prescribed hypnotics and the high number of over-the-counter sleep aids indicate that there is the potential for massive growth in sales of new hypnotics. Pharmaceutical companies have produced and, continue to develop, hypnotics and treatments for insomnia, and alerting medications to combat sleepiness, particularly daytime sleepiness.

However, there are different types of insomnia. Take, for example, transient insomnia. We are all aware that anxiety can bring on insomnia – perhaps if you are worried about the events of the next day. Or you may have insomnia because you’ve drunk too much coffee.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Martin King began his career in sleep medicine around 20 years ago, and has worked in the NHS and the private sector, and has spent a brief period in the US. He is a member of the World Association of Sleep Medicine, the European Sleep Research Society, American Academy of Sleep Medicine and the British Sleep Society. Martin was Manager of the UK’s largest clinical sleep laboratory and he has assessed thousands of patients across the spectrum of sleep disorders. He has authored papers in a number of peer reviewed journals and is regularly asked to contribute to teaching programmes. Martin recently joined LCG Bioscience in Cambridge, UK, to head the new sleep facility which is designed to deliver both early and late phase clinical trials
spacer
Martin King
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PRA Enhances COVID-19 Monitoring Program with Integration of Microsoft Healthcare Bot Service

PRA Health Sciences, Inc. announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement